|
|
||||||||
1 Exercise Physiology and Biomechanics Laboratory, Department of Kinesiology, Faculty of Physical Education and Physiotherapy, Katholieke Universiteit Leuven, B-3001 Heverlee; 2 Health and Nutrition Group, Eridania Béghin-Say, Vilvoorde, Belgium; and 3 Department of Physiology, Cardiovascular Research Institute, and 4 Department of Human Biology, Maastricht University, NL-6200 MD, Maastricht, The Netherlands
| |
ABSTRACT |
|---|
|
|
|---|
A double-blind randomized study was performed to evaluate the effect of oral ribose supplementation on repeated maximal exercise and ATP recovery after intermittent maximal muscle contractions. Muscle power output was measured during dynamic knee extensions with the right leg on an isokinetic dynamometer before (pretest) and after (posttest) a 6-day training period in conjunction with ribose (R, 4 doses/day at 4 g/dose, n = 10) or placebo (P, n = 9) intake. The exercise protocol consisted of two bouts (A and B) of maximal contractions, separated by 15 s of rest. Bouts A and B consisted of 15 series of 12 contractions each, separated by a 60-min rest period. During the training period, the subjects performed the same exercise protocol twice per day, with 3-5 h of rest between exercise sessions. Blood samples were collected before and after bouts A and B and 24 h after bout B. Knee-extension power outputs were ~10% higher in the posttest than in the pretest but were similar between P and R for all contraction series. The exercise increased blood lactate and plasma ammonia concentrations (P < 0.05), with no significant differences between P and R at any time. After a 6-wk washout period, in a subgroup of subjects (n = 8), needle-biopsy samples were taken from the vastus lateralis before, immediately after, and 24 h after an exercise bout similar to the pretest. ATP and total adenine nucleotide content were decreased by ~25 and 20% immediately after and 24 h after exercise in P and R. Oral ribose supplementation with 4-g doses four times a day does not beneficially impact on postexercise muscle ATP recovery and maximal intermittent exercise performance.
ergogenics; adenine nucleotides; ATP; ammonia; purine salvage
| |
INTRODUCTION |
|---|
|
|
|---|
PHOSPHOCREATINE BREAKDOWN by the action of creatine kinase (CK) is the primary pathway of ATP production during short periods of strenuous exercise. However, as muscle phosphocreatine concentration rapidly drops, the rate of ADP rephosphorylation through the CK reaction is impaired, which causes intracellular ATP content to decrease and ADP content to increase (2, 4, 10, 14, 15, 17, 20, 28). A fraction of this ADP is eventually degraded to IMP by the successive actions of adenylate kinase and AMP deaminase. A small proportion of the IMP so formed is converted to inosine and further to hypoxanthine, which implies a reduction of the muscle adenine nucleotide pool (8-10, 21, 24, 28). After a single bout of maximal exercise, the nucleotide pool is rapidly replenished via the purine salvage metabolic pathway in conjunction with the purine nucleotide cycle (1, 5, 12, 18, 28). This involves the conversion of hypoxanthine to IMP and further to AMP, eventually resulting in ATP resynthesis. However, during training involving many repeated bouts of high-intensity exercise, purine salvage and nucleotide cycling may fail to compensate for the massive rate of nucleotide degradation. Thus a small fraction of the nucleosides and bases are lost from the muscle cells and need to be replenished by de novo nucleotide synthesis. However, the latter process is slow, which explains the decrease in muscle ATP content for several days after exercise (10, 20). The formation of ribose 5-phosphate through the pentose phosphate pathway sets the upper pace of adenine nucleotide synthesis. There is evidence from animal studies that this limitation can be overcome by increasing ribose delivery to the muscle. In the perfused rat hindquarter, supraphysiological concentrations of ribose (5 mM) enhanced the formation of phosphoribosyl pyrophosphate, a precursor of IMP production and, thereby, ATP synthesis (27). Furthermore, increasing ribose by intravenous ribose infusion was found to markedly enhance the recovery of myocardial ATP content as well as the functional capacity in various animal models of myocardial ischemia (11, 13, 16, 22, 23, 26, 29-31).
The above-mentioned findings have prompted interest in the potential of oral ribose supplements to boost muscular performance in sports. Moreover, ribose supplements are being advertised to be "ergogenic" in athletic populations involved in high-intensity exercise training. Ribose is rapidly absorbed from the intestinal tract and is well tolerated, even at very high dosages (>100 g/day) (7) or during exercise (6). After absorption, ribose is rapidly and extensively metabolized, the principal fate being conversion in the liver to glucose via the pentose phosphate pathway (19). Furthermore, ribose can also be transported to muscle cells to feed the nucleotide synthesis pathway. However, there is no evidence that oral ribose intake can beneficially impact adenine nucleotide synthesis in skeletal musculature and/or enhance exercise performance in humans. Therefore, the goal of the present study was to evaluate the effect of a common oral ribose supplementation regimen on the restoration of muscle ATP after strenuous exercise, on the one hand, and on muscle force and power output during a training period involving repeated bouts of maximal exercise, on the other hand.
| |
METHODS |
|---|
|
|
|---|
Subjects. Twenty healthy male physical education students (20.6 ± 0.4 yr of age, 75.2 ± 1.6 kg body wt) gave their informed written consent to participate in the study. None of the volunteers had a specific background of sprint and/or resistance training, but all were regular participants in various sports activities involving sprint and resistance exercise. Exclusion criteria on admission were 1) prior ribose supplementation or intake of other nutritional supplements or medication and 2) any medical condition that might contraindicate heavy-resistance exercise with the right leg. The subjects were asked to avoid changes in their diet and level of physical activity during the period of the study. One subject withdrew because of a back injury, which prevented further participation in the exercise training sessions.
Study protocol. The study consisted of two phases (I and II), with a 6-wk washout period in between phases. The study protocol was approved by the local ethics committee.
In phase I, a double-blind placebo-controlled study was performed over a period of 12 days. Days 0-7 were exercise days, which were preceded by 4 days of placebo/ribose supplementation (days
4 to
1). One week
before day
4, the subjects reported to the laboratory for
familiarization with the exercise test procedures. On the basis of the
torque measurements in this preliminary session, the subjects were
assigned to two experimental groups with similar distributions for
maximal isometric torque and percent muscle fatigue (percent torque
decrease) during the maximal intermittent exercise test (see below).
After 1 wk (day
4), the ribose/placebo supplementation
period was started. On the morning of day 0, the subjects
reported to the laboratory after an overnight fast and received a
standardized breakfast. After 90 min, they performed the pretest. The
test consisted of two exercise bouts (A and B), which each consisted of 15 series of 12 maximal intermittent knee extensions with the right leg on an isokinetic dynamometer (see below)
with 1 h of rest between the bouts. During the 60-min rest period
between bouts A and B, the subjects first cycled
at ~100 W on a bicycle ergometer (Monark) for 15 min, and then they
rested in a semisupine position until the start of bout B.
Capillary blood samples (heparinized glass capillaries) from a
hyperemic earlobe (Forapin) and venous blood samples from an
antecubital vein (Vacutainer) were taken immediately before and after
bouts A and B and 24 h after bout
B. From day 1 to day 6, the subjects participated in a
standardized training program. On each day, they reported twice to the
laboratory, with 4-6 h between visits, and performed a training
session on the isokinetic dynamometer, which was similar to exercise
bout A (see above). However, on day 6, the
subjects performed only a single training session. On the next day
(day 7) and
24 h after the last training session on
day 6, they returned to the laboratory to perform the
posttest, which was identical to the pretest.
The goal of phase II was to evaluate the impact of the
intermittent exercise protocol on muscle adenine nucleotides. Sixteen of the 20 subjects who participated in phase I (20.3 ± 0.4 yr of age, 75.3 ± 1.9 kg body wt) agreed to participate in
phase II. After a 6-wk washout period following phase
I, a double-blind placebo-controlled study was performed over 3 days. Day
1 was a rest day, day 0 was an
exercise day, and day 1 was a recovery day. Subjects were
assigned to the ribose-treated (R) or placebo (P) group to obtain two
groups with similar distributions for maximal isometric torque, and
percent muscle fatigue was measured during the pretest of phase
I. On the morning of day 0, the subjects reported to
the laboratory after an overnight fast and received a standardized
breakfast. After 90 min, a biopsy was taken from the left vastus
lateralis muscle using a Bergström needle with suction applied.
To obtain the biopsy, an incision was made through the skin and muscle
fascia under local anesthesia (2-3 ml of 1% lidocaine).
Immediately thereafter, the subjects performed the exercise test
similar to phase I. However, the maximal isometric contractions before bout A and after bout B in
phase I were omitted. At 10 min before the start of
bout B, an incision was made through the skin and fascia of
the right vastus lateralis muscle. This incision was used to obtain a
biopsy within 2-3 min after bout B. After 24 h of
recovery (day 1), the subjects returned to the laboratory
for a muscle biopsy, which was taken ~3 cm proximal to the
postexercise biopsy site on day 2.
Diet and supplements. On the evening and morning before each exercise test, the subjects received a standardized dinner [855 kcal: 47% carbohydrate (CHO), 25% fat, 28% protein] and breakfast (320 kcal: 65% CHO, 15% fat, 20% protein), respectively. The ribose supplements (4 g) were mixed with maltodextrin (4.5 g), aspartame (250 mg), and artificial lemon flavor (23 mg) to be similar in taste and appearance to the placebo supplements (8.5 g maltodextrin, 250 mg aspartame, and 23 mg lemon flavor). At the end of the study, the subjects were asked whether they had any notion of the treatment they had received. Irrespective of the supplements received, all were unsure.
During phase I, the subjects from the R group (n = 10) received four 4-g oral ribose supplements each day (16 g/day); the other subjects (P group) received placebo supplements. On the resting days (day
4 to day
1), the subjects were instructed to ingest the supplements in
150 ml of water immediately before breakfast, lunch, and dinner and
1 h before bedtime. During the pretest (day 0) and the
posttest (day 7), the subjects ingested the supplements 10 min before and at the end of exercise bout A and immediately
after and 2 h after exercise bout B. During the
training days (days 1-6), the subjects ingested the
supplements immediately before and after each of the two daily training
sessions. During phase II, on day
1, the
subjects received four 4-g doses of ribose or placebo supplements
similar to phase I, and in the evening they were served a
standardized dinner (see above). On day 0, they arrived at
the laboratory after an overnight fast, and they received a
standardized breakfast 90 min before the exercise test similar to
phase I. They ingested the placebo/ribose supplements before
and after exercise bout A and 2 and 4 h after exercise bout B. They also received a standardized lunch (400 kcal:
60% CHO, 16% fat, 24% protein) and dinner. On day 1, they
returned to the laboratory for the 24-h recovery biopsy 2 h after
a standardized breakfast and a final 4-g ribose/placebo dose.
Knee-extension torque measurements. The subjects were seated on an isokinetic dynamometer in a backward (30°)-inclined chair (hip angle 90°) with the right knee supported at the level of the popliteal cavity. The dynamometer was instrumented with a torque transducer (Lebow 1605, 0.05% accuracy level) and connected with a rigid lever arm, which was positioned lateral to the lower leg, such that its axis was aligned with the knee joint axis. The leg was strapped to the lever arm of the system above the ankle. The positions of the knee and ankle fixations and of the axis of the measuring device were noted for each individual and were set to be identical for the pretest and the posttest and for phases I and II of the study. Subjects were asked to generate, from full relaxation and as fast as possible, maximal knee extensions (isometric or concentric) and thereafter relax as fast as possible. After a standardized 5-min warm-up, the test started with three maximal isometric contractions (3 s) at a knee angle of 120° (180° being full extension), separated by 1 min of rest. Immediately thereafter, they performed two intermittent exercise bouts (A and B), which each consisted of 15 series of 12 maximal knee extensions. The knee extensions were performed at a constant velocity of 60°/s, starting from 90° knee flexion to 150° knee extension. After each contraction, the leg was returned (240°/s) passively to the starting position, from which the next contraction was immediately initiated. The contraction series (15 s) were separated by 15-s rest intervals. A 60-min rest pause separated bouts A and B. Immediately after bout B, the subjects repeated the isometric contractions similar to those performed in bout A. For each contraction, torque was continuously digitized at 500 Hz and stored to disk for later analysis.
Biochemical measurements.
Capillary blood samples were immediately analyzed for lactate
concentration using a automated lactate analyzer (model 2300STAT, Yellow Springs Instruments). Venous blood samples were immediately centrifuged at 19,000 g to separate plasma from blood cells
within 3 min. A fraction (200 µl) of the plasma was immediately
extracted in 0.6 N perchloric acid. The plasma samples and the
perchloric acid extracts were stored at
20°C until analyzed at a
later date. Plasma ammonia concentration was assayed in the neutralized
perchloric acid extracts by a standard enzymatic fluorometric method
(3). Plasma CK activity and uric acid concentrations were
measured by automated routine clinical biochemistry laboratory
procedures (autoanalyzer model 917, Hitachi). Plasma ribose
concentration was assayed by Dionex HPLC. The muscle samples were
immediately blotted and cleaned of visible connective tissue or fat and
frozen in liquid nitrogen 1 min after excision. Thereafter samples were freeze-dried at
55°C for 48 h and stored at
80°C until
analyzed at a later date. Muscle ATP, ADP, AMP, IMP, and NAD content
was determined on neutralized perchloric acid extracts using HPLC (25). Total muscle adenine nucleotide (TAN) content was
calculated as the sum of ATP, ADP, AMP, and IMP content.
Statistical analyses. The effects of ribose supplementation vs. placebo in phase I were evaluated using a 2 × 2 × 5 [treatment (P and R) × exercise day (pretest and posttest) × time (before and after bout A, before and after bout B, and after 24 h of recovery)] three-way analysis of variance, which was covariate adjusted for the baseline values. In addition to these primary analyses, a one-way analysis of variance was performed to compare postexercise values with the corresponding baseline values within each treatment group. In phase II, a one-way analysis of variance was performed to compare postexercise and 24-h recovery values with the corresponding baseline values within each treatment group. P < 0.05 was the criterion for acceptance of statistical significance. Values are means ± SE.
| |
RESULTS |
|---|
|
|
|---|
Muscle power and force output.
In phase I, the subjects performed the intermittent maximal
knee-extension test before (pretest) and after (posttest) 6 days of
training. In the pretest, initial power was similar between P and R. Compared with initial power, power outputs at the end of bout
A and at the start and end of bout B were 39, 79, and 42% of initial power, respectively. Power outputs at the start and end
of each of the 15 series of 12 maximal contractions were similar
between P and R for bouts A and B (Fig.
1), which resulted in similar mean power
outputs (Fig. 2). During the posttest,
mean power output was, on average, ~18% higher than in the pretest for either exercise bout (Fig. 2). However, similar to the pretest, power outputs were similar between groups at any time. Immediately before and after the pretest and posttest, the subjects performed three
maximal isometric knee extensions. Figure
3 shows that maximal isometric torque was
~25% lower after than before the pretest, with no differences
between P and R. In the posttest, isometric torques were higher than in
the pretest, but again they were similar between groups. Muscle power
outputs were also measured during every training session from day
1 to day 6. Power outputs progressively increased
throughout the week but were similar between P and R at all times.
|
|
|
Muscle adenine nucleotides.
Adenine nucleotides were measured only in phase II of the
study, before and after the maximal intermittent exercise test. ATP,
ADP, AMP, and IMP concentrations before exercise were similar between P
and R (Table 1). The exercise decreased
muscle ATP content by 20-25% in both groups (P < 0.05). After 24 h of recovery, ATP content had slightly increased
(not significant) in P and R but was still significantly lower
(P < 0.05) than the corresponding baseline values.
Because muscle ADP, AMP, and IMP contents were not significantly
increased 2-3 min after exercise, muscle TAN content paralleled
the exercise-induced changes in ATP. Thus TAN was decreased
(P < 0.05) by 20-25% at 2-3 min after
exercise and 15-20% after 24 h of recovery in either
group (P < 0.05).
|
Blood and plasma metabolites.
The intermittent knee-extension exercise bouts each increased
(P < 0.05) blood lactate from ~0.8 mmol/l before to
~4-5 mmol/l immediately after exercise (Table
2). However, at any time, blood lactate
concentrations were similar between groups. By analogy, exercise
bouts A and B each increased (P < 0.05) plasma ammonia concentration to the same degree in P and R
(Table 2). Blood lactate and plasma ammonia also were similar for the
pretest and posttest. Plasma CK was increased in P and R 24 h
after the pretest (P < 0.05) but not after the
posttest (Table 3). Neither the pretest
nor the posttest significantly changed plasma uric acid concentration
in either experimental condition. Plasma ribose concentration was only
assayed in R immediately before bouts A and B of
the pretest. Initial plasma ribose concentration was 7 (range
0-17) µmol/l and increased to 93 (range 19-303) µmol/l before bout B. No side effects related to the ribose
supplementation were reported over the duration of the study.
|
|
| |
DISCUSSION |
|---|
|
|
|---|
This study evaluated the effect of oral ribose supplementation on muscle ATP concentration after a single exhaustive intermittent exercise session and on muscle force and power output during a training period involving many repeated maximal intermittent exercise bouts. It was hypothesized that ribose administration enhances postexercise ATP recovery by stimulating de novo ATP synthesis and, via this mechanism, increases muscle performance during high-intensity intermittent training. The exercise test caused a significant net loss of adenine nucleotides from the quadriceps muscle, as evidenced by a ~20% lower ATP content 24 h after exercise (Table 1). Conversely, published literature indicates that successive days of repeated high-intensity training (10, 20), but not single sprint-exercise sessions, can cause muscle ATP content to be decreased for >24 h after exercise. However, the number of intermittent sprint bouts performed in the present study (30 "sprints" involving 12 maximal knee extensions each) was much higher than in any earlier study (1, 9, 15, 17, 21, 28). Clear evidence has been provided that the loss of purines from muscle is enhanced with increasing number of successive sprints to be performed (21). In addition, the strain imposed on the quadriceps muscle, the site of biopsy sampling, during maximal unilateral knee extensions is conceivably higher than that during whole body sprint exercise (18, 21, 28). Thus, despite the fact that the exercise involved only a small muscle mass, it caused a nearly fourfold rise of systemic arterial lactate concentration. In addition, plasma ammonia, an extracellular marker of muscle adenine nucleotide catabolism, was significantly increased (Table 2). However, administration of oral ribose supplements did not alter the exercise-induced changes of muscle ATP content immediately after or 24 h after exercise. The reason for the low ATP values measured in the present study is unclear. However, NAD concentrations measured in the muscle biopsies were normal and constant at all times, which proves the validity of the ATP and TAN changes measured. Thus four doses of oral ribose at 4 g each within a 4-h window after the exercise test clearly failed to beneficially impact purine nucleotide metabolism during the strenuous exercise conditions used in the present study.
If ribose administration does not facilitate postexercise adenine nucleotide resynthesis, then exercise capacity cannot be improved via this mechanism. We measured maximal torque and power output during an 8-day training period that consisted of the pretest (day 0) and the posttest (day 7), with 6 days of high-intensity training between test days (2 daily training sessions). For the pretest, the training days, and the posttest, muscle power outputs were similar between the P and R group. Ribose intake did not alter mean power production for either of the two intermittent exercise bouts (A and B), which were separated by 1 h of rest (Fig. 1). In addition, it failed to enhance power recovery during the short rest intervals (15 s) between the maximal contraction series within each bout (Fig. 2). Furthermore, maximal isometric force was similar between R and P before exercise and after fatigue due to the intermittent exercise test (Fig. 3). Thus this study clearly shows that intake of ribose at 16 g/day, in the conditions of the present study, did not enhance maximal muscle force and power production during maximal intermittent muscle contractions.
Zarzeczny and co-workers (27) previously demonstrated that increasing perfusate ribose concentration from ~0 to ~5 mmol/l increased nucleotide synthesis rate in perfused rat skeletal muscles. Such a high plasma ribose concentration conceivably cannot be established in humans by oral ribose intake. First, the ribose intakes required would be beyond the limits of gastrointestinal tolerance. Second, because of the very rapid clearance of plasma ribose (19), it is very difficult to obtain high and stable plasma ribose levels by oral ribose ingestion. (32). In the present study, subjects ingested 4 g of ribose immediately before and after a 15-min intermittent exercise bout. Plasma ribose concentration measured 1 h after the last dose on average was <0.1 mmol/l, which is conceivably too low to significantly enhance muscle ribose uptake to stimulate purine nucleotide synthesis. We cannot exclude the possibility that substantially higher ribose intake rates than used here, if well tolerated, might enhance postexercise ATP recovery in humans. However, our findings provide strong evidence to suggest that the ribose doses used by athletes result in plasma ribose levels that are too low to allow for an ergogenic action. Our ribose administration regimen (4 doses at 4 g each) was even higher than that recommended for most, if not all, commercial ribose preparations.
In conclusion, oral ribose supplementation at 16 g (4 doses at 4 g each) per day does not beneficially impact muscle ATP recovery and muscle force and power output during repeated days of maximal intermittent exercise training.
| |
ACKNOWLEDGEMENTS |
|---|
This study was supported by a grant from Eridania Bégin-Say, Health and Nutrition, Research and Development (Vilvoorde, Belgium).
| |
FOOTNOTES |
|---|
Address for reprint requests and other correspondence: P. Hespel, Exercise Physiology and Biomechanics Laboratory, Faculty of Physical Education and Physiotherapy, Tervuursevest 101, B-3001 Heverlee, Belgium.
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 14 December 2000; accepted in final form 22 June 2001.
| |
REFERENCES |
|---|
|
|
|---|
1.
Bangsbo, J,
Gollnick PD,
Graham TE,
Juel C,
Kiens B,
Mizuno M,
and
Saltin B.
Anaerobic energy production and O2 deficit-debt relationship during exhaustive exercise in humans.
J Physiol (Lond)
422:
539-559,
1990
2.
Bangsbo, J,
Graham T,
Johansen L,
Strange S,
Christensen C,
and
Saltin B.
Elevated muscle acidity and energy production during exhaustive exercise in humans.
Am J Physiol Regulatory Integrative Comp Physiol
263:
R891-R899,
1992
3.
Bangsbo, J,
Graham TE,
Kiens B,
and
Saltin B.
Elevated muscle glycogen and anaerobic energy production during exhaustive exercise in man.
J Physiol (Lond)
451:
205-227,
1992
4.
Bogdanis, GC,
Nevill ME,
Boobis LH,
Lakomy HKA,
and
Nevill AM.
Recovery of power output and muscle metabolites following 30 s of maximal sprint cycling in man.
J Physiol (Lond)
482:
467-480,
1995[ISI][Medline].
5.
Broberg, S,
Katz A,
and
Sahlin K.
Propranolol enhances adenine nucleotide degradation in human muscle during exercise.
J Appl Physiol
65:
2478-2483,
1988
6.
Gross, M,
Kormann B,
and
Zöllner N.
Ribose administration during exercise: effects on substrates and products of energy metabolism in healthy subjects and a patient with myoadenylate deaminase deficiency.
Klin Wochenschr
69:
151-155,
1991[ISI][Medline].
7.
Gross, M,
Reiter S,
and
Zöllner N.
Metabolism of D-ribose administered continuously to healthy persons and to patients with myoadenylate deaminase deficiency.
Klin Wochenschr
67:
1205-1213,
1989[ISI][Medline].
8.
Hellsten, Y.
Xanthine dehydrogenase and purine metabolism in man, with special reference to exercise.
Acta Physiol Scand Suppl
151:
1-73,
1994[ISI][Medline].
9.
Hellsten, Y,
Richter EA,
Kiens B,
and
Bangsbo J.
AMP deamination and purine exchange in human skeletal muscle during and after intense exercise.
J Physiol (Lond)
520:
909-920,
1999
10.
Hellsten-Westling, Y,
Norman B,
Balsom PD,
and
Sjödin B.
Decreased resting levels of adenine nucleotides in human skeletal muscle after high-intensity training.
J Appl Physiol
74:
2523-2528,
1993
11.
Ibel, H,
and
Zimmer H-G.
Metabolic recovery following temporary regional myocardial ischemia in the rat.
J Mol Cell Cardiol
18:
61-65,
1986.
12.
Katz, A,
Sahlin K,
and
Henriksson J.
Muscle ammonia metabolism during isometric contractions.
Am J Physiol Cell Physiol
250:
C834-C840,
1986
13.
Mauser, M,
Hoffmeister HM,
Nienaber C,
and
Schaper W.
Influence of ribose, adenosine, and "AICAR" on the rate of myocardial adenosine triphosphate synthesis during reperfusion after coronary artery occlusion in the dog.
Circ Res
56:
220-230,
1985
14.
McCartney, N,
Spriet LL,
Heigenhauser GJF,
Kowalchuk JM,
Sutton JR,
and
Jones NL.
Muscle power and metabolism in maximal intermittent exercise.
J Appl Physiol
60:
1164-1169,
1986
15.
Nevill, ME,
Boobis LH,
Brooks S,
and
Williams C.
Effect of training on muscle metabolism during treadmill sprinting.
J Appl Physiol
67:
2376-2382,
1989
16.
Pasque, MK,
Spray TL,
Pellom GL,
Van Tirgt P,
Peyton RB,
Currie WD,
and
Wechsler AS.
Ribose-enhanced myocardial recovery following ischemia in the isolated working rat heart.
J Thorac Cardiovasc Surg
83:
390-398,
1982[Abstract].
17.
Sahlin, K,
Harris RC,
and
Hultman E.
Resynthesis of creatine phosphate in human muscle after exercise in relation to intramuscular pH and availability of oxygen.
Scand J Clin Lab Invest
39:
551-558,
1979[ISI][Medline].
18.
Sahlin, K,
Palmskog G,
and
Hultman E.
Adenine nucleotide and IMP contents of the quadriceps muscle in man after exercise.
Pflügers Arch
374:
193-198,
1978[ISI][Medline].
19.
Segal, S,
and
Foley J.
The metabolism of D-ribose in man.
J Clin Invest
37:
719-735,
1958.
20.
Stathis, CG,
Febbraio MA,
Carey MF,
and
Snow RJ.
Influence of sprint training on human skeletal muscle purine nucleotide metabolism.
J Appl Physiol
76:
1802-1809,
1994
21.
Stathis, CG,
Zhao S,
Carey MF,
and
Snow RJ.
Purine loss after repeated sprint bouts in humans.
J Appl Physiol
87:
2037-2042,
1999
22.
St. Cyr, JA,
Bianco RW,
Schneider JR,
Mahoney JR,
Tveter K,
Einzig S,
and
Foker JE.
Enhanced high-energy phosphate recovery with ribose infusion after global myocardial ischemia in a canine model.
J Surg Res
46:
157-162,
1989[ISI][Medline].
23.
Tan, ZT,
and
Wang XW.
Verapamil, ribose and adenine enhance resynthesis of postischemic myocardial ATP.
Life Sci
55:
345-349,
1994.
24.
Tullson, PC,
Bangsbo J,
Hellsten Y,
and
Richter EA.
IMP metabolism in human skeletal muscle after exhaustive exercise.
J Appl Physiol
78:
146-152,
1995
25.
Van der Vusse, GJ,
Coumans WA,
Van der Veen E,
Drake AJ,
Flameng W,
and
Suy R.
ATP, creatine phosphate and glycogen content in human myocardial biopsies: marker for the efficacy of cardioprotection during aorto-coronary bypass surgery (Abstract).
Vasc Surg
18:
127-134,
1984.
26.
Ward, HB,
St. Cyr JA,
Cogordan JA,
Alyono D,
Bianco RW,
Kriett JM,
and
Foker JE.
Recovery of adenine nucleotide levels after global myocardial ischemia in dogs.
Surgery
96:
248-255,
1984[ISI][Medline].
27.
Zarzeczny, R,
Brault J,
Abraham K,
Hancock C,
and
Terjung RL.
Purine salvage is not reduced during recovery following intense contractions (Abstract).
Med Sci Sports Exerc
32:
S73,
2000.
28.
Zhao, S,
Snow RJ,
Stathis CG,
Febbraio MA,
and
Carey MF.
Muscle adenine nucleotide metabolism during and in recovery from maximal exercise in humans.
J Appl Physiol
88:
1513-1519,
2000
29.
Zimmer, H-G.
Significance of the 5-phosphoribosyl-1-pyrophosphate pool for cardiac purine and pyrimidine nucleotide synthesis: studies with ribose, adenine, inosine, and orotic acid in rats.
Cardiovasc Drugs Ther
12:
179-187,
1998.
30.
Zimmer, H-G,
and
Gerlach E.
Stimulation of myocardial adenine nucleotide biosynthesis by pentoses and pentitols.
Pflügers Arch
376:
223-227,
1978[ISI][Medline].
31.
Zimmer, H-G,
Martius PA,
and
Marschner G.
Myocardial infarction in rats: effects of metabolic and pharmacologic interventions.
Basic Res Cardiol
84:
332-343,
1989[ISI][Medline].
32.
Zöllner, N,
Reiter S,
Gross M,
Pongratz D,
Reimers CD,
Gerbitz K,
Paetzke I,
Deufel T,
and
Hübner G.
Myoadenylate deaminase deficiency: successful symptomatic therapy by high-dose oral administration of ribose.
Klin Wochenschr
64:
1281-1290,
1986[ISI][Medline].
This article has been cited by other articles:
![]() |
A. N. Kavazis, J. Kivipelto, H. S. Choe, P. T. Colahan, and E. A. Ott Effects of ribose supplementation on selected metabolic measurements and performance in maximally exercising Thoroughbreds J Anim Sci, February 1, 2004; 82(2): 619 - 625. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Hellsten, L. Skadhauge, and J. Bangsbo Effect of ribose supplementation on resynthesis of adenine nucleotides after intense intermittent training in humans Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2004; 286(1): R182 - R188. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |